IBRX vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jun 24, 2026

IBRX

64.6
AI Score
VS
IBRX Wins

MRNA

60.1
AI Score

Investment Advisor Scores

IBRX

Jun 24, 2026
65score
Recommendation
BUY

MRNA

Jun 24, 2026
60score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric IBRX MRNA Winner
Forward P/E 0 23.0415 Tie
PEG Ratio 0 0 Tie
Revenue Growth 167.6% 260.2% MRNA
Earnings Growth 0.0% -85.1% IBRX
Tradestie Score 64.6/100 60.1/100 IBRX
Profit Margin 0.0% -143.6% IBRX
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation BUY BUY Tie

Frequently Asked Questions

Based on our detailed analysis, IBRX is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.